These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 39157746)

  • 21. Contezolid can replace linezolid in a novel combination with bedaquiline and pretomanid in a murine model of tuberculosis.
    Almeida D; Li S-Y; Lee J; Hafkin B; Mdluli K; Fotouhi N; Nuermberger EL
    Antimicrob Agents Chemother; 2023 Dec; 67(12):e0078923. PubMed ID: 37966090
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Linezolid-induced pure red cell aplasia: a case report and literature review.
    Luo Z; Xu N; Wang Y; Huang X; Cao C; Chen L
    J Int Med Res; 2018 Nov; 46(11):4837-4844. PubMed ID: 30270705
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Determination of in vitro synergy between linezolid and other antimicrobial agents against Mycobacterium tuberculosis isolates.
    Zou L; Liu M; Wang Y; Lu J; Pang Y
    Tuberculosis (Edinb); 2015 Dec; 95(6):839-842. PubMed ID: 26395151
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Contezolid, a novel oxazolidinone antibiotic, may improve drug-related thrombocytopenia in clinical antibacterial treatment.
    Li B; Liu Y; Luo J; Cai Y; Chen M; Wang T
    Front Pharmacol; 2023; 14():1157437. PubMed ID: 37168994
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bedaquiline, Delamanid, Linezolid, Clofazimine, and Capreomycin MIC Distributions for Drug Resistance
    Guo Y; Yang J; Wang W; Wu X; Wan B; Wang H; Sha W; Yu F
    Infect Drug Resist; 2023; 16():7587-7595. PubMed ID: 38107433
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Linezolid as a Potentially Effective Drug for the Treatment of Multidrug-Resistant Tuberculosis in Japan.
    Yi L; Yoshiyama T; Okumura M; Morimoto K; Sasaki Y; Shiraishi Y; Ogata H; Mitarai S
    Jpn J Infect Dis; 2017 Jan; 70(1):96-99. PubMed ID: 27000461
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preclinical toxicity evaluation of novel antibacterial contezolid acefosamil in rats and dogs.
    Wang W; Li Z; Gordeev MF; Yuan H
    J Appl Toxicol; 2024 May; 44(5):770-783. PubMed ID: 38237604
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reversible recurrent profound thrombocytopenia due to linezolid in a patient with multi-drug resistant tuberculosis: A case report.
    Wang MG; Wang D; He JQ
    Medicine (Baltimore); 2018 Aug; 97(34):e11997. PubMed ID: 30142839
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomised trial to evaluate the effectiveness and safety of varying doses of linezolid with bedaquiline and pretomanid in adults with pre-extensively drug-resistant or treatment intolerant/non-responsive multidrug-resistant pulmonary tuberculosis: study protocol.
    Padmapriyadarsini C; Devaleenal B; Ponnuraja C; Ramraj B; Singla R; Parmar M; Mattoo S; Mandal S
    BMJ Open; 2022 Aug; 12(8):e058606. PubMed ID: 36038181
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Linezolid Pharmacokinetics and Its Association with Adverse Drug Reactions in Patients with Drug-Resistant Pulmonary Tuberculosis.
    Padmapriyadarsini C; Solanki R; Jeyakumar SM; Bhatnagar A; Muthuvijaylaksmi M; Jeyadeepa B; Reddy D; Shah P; Sridhar R; Vohra V; Bhui NK
    Antibiotics (Basel); 2023 Apr; 12(4):. PubMed ID: 37107075
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discovery of Antibacterial Contezolid Acefosamil: Innovative
    Liu J; Wang W; Wang C; Zhang L; Zhang X; Liu S; Xu Y; Wang H; Dai Q; Liu C; Wang X; Yuan Z; Gordeev MF
    ACS Med Chem Lett; 2022 Jul; 13(7):1030-1035. PubMed ID: 35859881
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Susceptibility testing of extensively drug-resistant and pre-extensively drug-resistant Mycobacterium tuberculosis against levofloxacin, linezolid, and amoxicillin-clavulanate.
    Ahmed I; Jabeen K; Inayat R; Hasan R
    Antimicrob Agents Chemother; 2013 Jun; 57(6):2522-5. PubMed ID: 23507286
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Peripheral neuropathy in a diabetic child treated with linezolid for multidrug-resistant tuberculosis: a case report and review of the literature.
    Swaminathan A; du Cros P; Seddon JA; Mirgayosieva S; Asladdin R; Dusmatova Z
    BMC Infect Dis; 2017 Jun; 17(1):417. PubMed ID: 28606115
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Linezolid-Induced Pure Red Cell Aplasia: A Case Report.
    Yang XY; Chen L; Gu JN; Zeng CJ; Pan DM
    Infect Drug Resist; 2022; 15():3847-3856. PubMed ID: 35899083
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adverse drug reactions due to linezolid in the programmatic management of drug-resistant tuberculosis in India: A retrospective multicenter study.
    Mishra G; Alffenaar JW; Munje R; Khateeb S
    Indian J Tuberc; 2024; 71 Suppl 1():S101-S109. PubMed ID: 39067941
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Contezolid in complicated skin and soft tissue infection.
    Kaul G; Dasgupta A; Chopra S
    Drugs Today (Barc); 2022 Jul; 58(7):315-326. PubMed ID: 35851867
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-Term Intake of Linezolid Elevates Drug Exposure and Reduces Drug Clearance and Elimination in Adults With Drug-Resistant Pulmonary Tuberculosis.
    Jeyakumar SM; Bhui NK; Singla N; Vilvamani S; Mariappan MV; Padmapriyadarsini C; Bhatnagar AK; Solanki R; Sridhar R
    Ther Drug Monit; 2023 Dec; 45(6):754-759. PubMed ID: 37296501
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Study on the resistance of rifampicin-resistant Mycobacterium tuberculosis to anti-tuberculosis drugs in group A].
    Dai XW; Li CY; Wang NH; Chen SS; Tian LL; Zhao YF; Tao LY; Yang XY; Ding BC; He XX
    Zhonghua Jie He He Hu Xi Za Zhi; 2023 Nov; 46(11):1110-1117. PubMed ID: 37914422
    [No Abstract]   [Full Text] [Related]  

  • 39. The emerging threat of fluroquinolone-, bedaquiline-, and linezolid-resistant Mycobacterium tuberculosis in China: Observations on surveillance data.
    Li S; Tan Y; Deng Y; Bai G; Huang M; Shang Y; Wang Y; Xue Z; Zhang X; Wang W; Pan J; Pang Y
    J Infect Public Health; 2024 Jan; 17(1):137-142. PubMed ID: 38000314
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel oxazolidinones harbor potent
    Wang C; Wang G; Huo F; Xue Y; Jia J; Dong L; Zhao L; Wang F; Huang H; Duan H
    Front Med (Lausanne); 2022; 9():1067516. PubMed ID: 36523787
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.